AVTE Stock Forecast, Price Targets, Chart, Dividends & Analysis
Aerovate Therapeutics Inc
AVTE 
NSD
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
2.61
USD
-0.05
(-1.88%)
Previous close: 2.66 Open: 2.65 Bid: 2.55 Ask: 2.84
52 week range
1.25 32.42
Mkt Cap: 77 M Avg Vol (90 Days): 792,380
Last updated: Friday 22nd November 2024
Metrics
Valuation
Returns
7 Day Return | 1.95% | |
1 Month Return | 20.28% | |
3 Month Return | 39.57% | |
1 Year Return | -82.92% | |
3 Year Return | -81.41% | |
5 Year Return | -88.57% | |
YTD Return | -88.47% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 57.45 |
14 Day SMA ($) | 2.65 |
14 Day EMA ($) | 2.58 |
Money Flow Index | 40.36 |
Average True Range | 0.13 |
50 Day SMA ($) | 2.27 |
200 Day SMA ($) | 11.11 |
ADX | 50.72 |
MACD | -1.14 |
Growth
Free Cash Flow QoQ Growth | 0.00% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 0.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Financials
AVTE Income Statement
Annual
| Invalid date | Dec-21 | Dec-22 | Dec-23 | |
|---|---|---|---|---|
| AccretionOnPreferredStock | 22000.0 | |||
| Basic EPS from continuing operations | -1.87 | -2.1 | -2.87 | |
| Basic EPS total | -1.87 | -2.1 | -2.87 | |
| Basic weighted shares outstanding | 12 M | 24 M | 26 M | |
| Depletion | 407000.0 | |||
| Depreciation unreconciled | 407000.0 | |||
| Diluted EPS total | -1.87 | -2.1 | -2.87 | |
| Diluted normalized net income/share | -2.1 | -2.87 | ||
| Diluted weighted shares outstanding | 24 M | 26 M | ||
| GainOnSaleOfSecurity | 113 M | |||
| GeneralAndAdministrativeExpense | 8 M | 15 M | 17 M | |
| Income before tax | -23 M | -51 M | -75 M | |
| Income taxes | 3000.0 | 25000.0 | 56000.0 | |
| Interest income | 65000.0 | 2 M | 6 M | |
| InterestExpenseOperating | 59000.0 | |||
| MiscOtherSpecialCharges | -3000.0 | -79000.0 | -1000.0 | |
| Net income from total operations | -23 M | -52 M | -76 M | |
| NetIncomeCommonStockholders | -23 M | -52 M | -76 M | |
| NetIncomeContinuousOperations | -23 M | -52 M | -76 M | |
| NetNonOperatingInterestIncomeExpense | 65000.0 | 2 M | 6 M | |
| Normalized income | -18 M | -60 M | ||
| Operating income | -23 M | -53 M | -81 M | |
| Operating income before depreciation (EBITDA) | -23 M | -52 M | -81 M | |
| OperatingExpense | 23 M | 53 M | 81 M | |
| Other income net | 3000.0 | 486000.0 | -1000.0 | |
| OtherGandA | 8 M | 15 M | 17 M | |
| OtherOperatingExpenses | -253000.0 | -461000.0 | -1 M | |
| OtherunderPreferredStockDividend | 22000.0 | |||
| PreferredStockDividends | 22000.0 | |||
| Research & development expense | 15 M | 39 M | 64 M | |
| ResearchExpense | 15 M | 39 M | 64 M | |
| SalariesAndWages | 2 M | 5 M | 12 M | |
| Selling Gen & administrative expense | 8 M | 15 M | 17 M | |
| Total Income available for interest expense (EBIT) | -23 M | -51 M | -81 M | |
| Total common shares outstanding | 24 M | 25 M | ||
| Total net income | -23 M | -52 M | -76 M | |
| Total ordinary shares | 29 M | 29 M | 29 M | |
| TotalExpenses | 23 M | 53 M | 81 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS is a complete Excel stock solution
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel
MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.
I like to access historical closing prices on a particular date. That makes tracking performance easy.